Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study

Autor:	Fuyuki Tateno, Shigekazu Hirai, Yohei Tsuyusaki, Tohru Masaka, Hirokazu Doi, Mitsutoshi Sato, Osamu Takahashi, Ryuji Sakakibara, Masahiko Kishi, Akihiko Tateno, Tsuyoshi Ogata
Rok vydání:	2013
Předmět:	Breath test Abdominal pain Parkinson's disease medicine.diagnostic_test Gastric emptying business.industry medicine.disease Neurology Anesthesia medicine Neurology (clinical) Gastroparesis Expiration medicine.symptom Adverse effect business Nizatidine medicine.drug
Zdroj:	Movement Disorders. 29:562-566
ISSN:	0885-3185
DOI:	10.1002/mds.25777
Popis:	Background The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a 13C-sodium acetate expiration breath test. Methods Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test. Results NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax (13C) (the peak time of the 13C-dose-excess curve) (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a06e8fd9500624dbc058170cf0fed3cc https://doi.org/10.1002/mds.25777 Zobrazit plný text záznamu Plný text